K Number
K233855
Device Name
AllPEP
Date Cleared
2024-02-02

(59 days)

Product Code
Regulation Number
868.5690
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The Enchant AllPEP is intended for use as a Positive Expiratory Pressure (PEP) by patients aged 18 years and older. Patients must be capable of generating an exhalation flow of 10 lpm for 3-4 seconds to promote secretion clearance. This device may be used to prevent or reverse atelectasis and as an inspiratory, deep breathing positive exerciser. It may be used in hospital and clinical settings.
Device Description
AllPEP provides PEEP during user exhalation and features a mechanism which provides oscillations during exhalation as well. Principle of Operation: The oscillating positive exhalation pressure device, AllPEP, includes a housing, a top cover, and an oscillating mechanism. The patient inhales room air through a one-way valve and when exhaling the exhaled gas is directed through the upper portion of the device which contains a swinger mechanism to oscillate the air, causing the air to vibrate.
More Information

Not Found

No
The description focuses on mechanical principles (swinger mechanism, one-way valve) and does not mention any computational or learning components.

Yes
The device is intended to treat conditions like atelectasis and promote secretion clearance, which are therapeutic actions.

No

The device is described as a Positive Expiratory Pressure (PEP) device intended to promote secretion clearance, prevent or reverse atelectasis, and act as an inspiratory/deep breathing exerciser. Its function involves providing oscillating positive exhalation pressure to aid in respiratory therapy, not to diagnose a condition.

No

The device description clearly outlines physical components like a housing, top cover, and oscillating mechanism, indicating it is a hardware device.

Based on the provided information, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use is for Positive Expiratory Pressure (PEP) to promote secretion clearance, prevent or reverse atelectasis, and as an inspiratory exerciser. This is a therapeutic and rehabilitative use, not a diagnostic one.
  • Device Description and Principle of Operation: The device works by providing positive pressure and oscillations during exhalation to affect the respiratory system. It does not analyze biological samples (like blood, urine, or tissue) to provide diagnostic information.
  • Lack of Diagnostic Elements: There is no mention of analyzing samples, detecting biomarkers, or providing any kind of diagnostic result.
  • Performance Studies: The performance studies focus on the physical characteristics and function of the device (pressure, frequency, amplitude, aging, cleaning), which are relevant to a therapeutic device, not a diagnostic one.

In vitro diagnostics are devices used to examine specimens taken from the human body to provide information for diagnosis, monitoring, or screening. The Enchant AllPEP does not fit this description.

N/A

Intended Use / Indications for Use

The Enchant AllPEP is intended for use as a Positive Expiratory Pressure (PEP) by patients aged 18 years and older. Patients must be capable of generating an exhalation flow of 10 lpm for 3-4 seconds to promote secretion clearance. This device may be used to prevent or reverse atelectasis and as an inspiratory, deep breathing positive exerciser. It may be used in hospital and clinical settings.

Product codes

BWF

Device Description

AllPEP provides PEEP during user exhalation and features a mechanism which provides oscillations during exhalation as well.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

18 years and older

Intended User / Care Setting

hospital and clinical settings

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Bench testing -
The following tests were performed to demonstrate substantial equivalence:

  • Aging and post-aging performance ●
  • Cleaning validation ●
  • Post-cleaning performance
  • Frequency (Hz)
  • Amplitude (cmH20) ●
  • Pressure at min / max settings (cmH20) 0
    Discussion - The test results are similar to the predicate and within pre-defined acceptance criteria.

Biocompatibility -
According to ISO 10993-1 and the FDA Guidance related to biocompatibility from 2020, the subject device is considered:

  • External Communicating
  • Tissue Contacting
  • Prolonged duration of use (>24 hours, 24 hours,

§ 868.5690 Incentive spirometer.

(a)
Identification. An incentive spirometer is a device that indicates a patient's breathing volume or flow and that provides an incentive to the patient to improve his or her ventilation.(b)
Classification. Class II (performance standards).

0

Image /page/0/Picture/0 description: The image contains the logos of the Department of Health and Human Services and the Food and Drug Administration (FDA). The Department of Health and Human Services logo is on the left, and the FDA logo is on the right. The FDA logo includes the letters "FDA" in a blue square, followed by the words "U.S. Food & Drug Administration" in blue text.

February 2, 2024

Enchant Tek Co. Ltd. Leonard Ling QA/RA Supervisor No. 210 Xiangzhong Rd. Dongshan Township Yilan County, 26950 Taiwan

Re: K233855

Trade/Device Name: AllPEP Regulation Number: 21 CFR 868.5690 Regulation Name: Incentive Spirometer Regulatory Class: Class II Product Code: BWF Dated: December 4, 2023 Received: December 5, 2023

Dear Leonard Ling:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

1

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Rachana Visaria -S

Rachana Visaria, Ph.D. Assistant Director DHT1C: Division of Sleep Disordered Breathing, Respiratory and

2

Anesthesia Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

3

Indications for Use

510(k) Number (if known) K233855

Device Name AllPEP

Indications for Use (Describe)

The Enchant AllPEP is intended for use as a Positive Expiratory Pressure (PEP) by patients aged 18 years and older. Patients must be capable of generating an exhalation flow of 10 lpm for 3-4 seconds to promote secretion clearance. This device may be used to prevent or reverse atelectasis and as an inspiratory, deep breathing positive exerciser. It may be used in hospital and clinical settings.

Type of Use (Select one or both, as applicable)
☑ Prescription Use (Part 21 CFR 801 Subpart D)☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

4

Date Prepared:February 2, 2024
Sponsor:Enchant Tek Co. Ltd.
No. 210 Xiangzhong Rd.
Dongshan Township, Yilan County
Taipei, TW 26950
Tel +886- 03-959-3500
Sponsor Contact:Ling Leonard - QA/RA Supervisor
Submission Correspondent:Paul Dryden
ProMedic, LLC
Proprietary or Trade Name:AllPEP
Common/Usual Name:PEP device
Classification Name:Spirometer, therapeutic (incentive)
Product Code:21CFR 868.5690
BWF
Predicate Device:DHD Acapella K991561
Common/Usual Name:Spirometer, therapeutic (incentive)
Classification Name:21CFR 868.5690
Product Code:BWF

Device Description: AllPEP provides PEEP during user exhalation and features a mechanism which provides oscillations during exhalation as well.

Principle of Operation: The oscillating positive exhalation pressure device, AllPEP, includes a housing, a top cover, and an oscillating mechanism. The patient inhales room air through a one-way valve and when exhaling the exhaled gas is directed through the upper portion of the device which contains a swinger mechanism to oscillate the air, causing the air to vibrate.

Indications for Use:

The Enchant AllPEP is intended for use as a Positive Expiratory Pressure (PEP) by patients aged 18 years and older. Patients must be capable of generating an exhalation flow of 10 lpm for 3-4 seconds to promote secretion clearance. This device may be used to prevent or reverse atelectasis and as an inspiratory, deep breathing positive exerciser. It may be used in hospital and clinical settings.

Patient Population:

Patients 18 years and older who are capable of generating an exhalation flow of 10 1pm for 3-4 seconds.

5

Environments of use:

For hospital and clinical settings.

Substantial Equivalence Discussion

The table below compares the key features of the proposed with the identified predicate - DHD Acapella K991561. The comparison demonstrates that the subject device is substantially equivalent to the predicate device.

. Indications for Use -

The indications for use are similar for the subject device when compared to the predicate device.

Discussion - Since the predicate, newer cleared PEP devices have more details within the indications for use. We have added this information, it does not however raise different questions of safety or effectiveness.

. Technology and construction -

The technology and principle of operation is similar for the subject device when compared to the predicate device.

Discussion - While the predicate may have a different means of creating oscillation, there are a number of cleared PEP devices which also have slightly different ways of creating oscillations during the exhalation cycle. This difference does not raise different concerns of safety or effectiveness.

. Environment of Use -

The environments of use are similar to predicate which are hospital and clinical settings. Discussion - The environments of use are similar.

Patient Population -.

The patient population for the subject device is patients requiring secretion clearance and those who may have atelectasis. They should be capable of generating an exhalation flow of 10 lpm for 3-4 seconds.

Discussion - The subject and predicate device patient populations are similar.

Non-Clinical Testing Summary -

Bench testing -

The following tests were performed to demonstrate substantial equivalence:

  • Aging and post-aging performance ●
  • Cleaning validation ●
  • Post-cleaning performance
  • Frequency (Hz)
  • Amplitude (cmH20) ●
  • Pressure at min / max settings (cmH20) 0

Discussion - The test results are similar to the predicate and within pre-defined acceptance criteria.

6

Biocompatibility -

According to ISO 10993-1 and the FDA Guidance related to biocompatibility from 2020, the subject device is considered:

  • External Communicating
  • Tissue Contacting
  • Prolonged duration of use (>24 hours, 24 hours, 24 hours,